Compare Prospect Capital Corporation (PSEC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Summit Therapeutics Inc — how do they compare? Prospect Capital Corporation trades at $1.74 (market cap $974.22M), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 14.1× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Summit Therapeutics Inc for 16 Days on average.
| PSEC | SMMT | |
|---|---|---|
Market Cap | $974.22M | $13.71B |
Volume | 5,779,996 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $3.05 | $26.38 |
52-Week Low | $1.82 | $12.43 |
Typical Hold Time | 78 Days | 16 Days |
Enterprise Value | $2.73B | $13.04B |
Dividend Yield | 23.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.72, down 6.52% today, amid bearish technical signals and mixed fundamentals. The stock shows consistent earnings beats but faces revenue volatility with negative 2025 results. Recent news highlights dividend distributions and portfolio management activity, while analysts remain cautious with 55% hold ratings. Technical indicators show oversold conditions with RSI below 10, but moving averages signal continued downward pressure.
PSEC presents a high-risk opportunity with an 18%+ yield and deep NAV discount, but faces significant headwinds from portfolio contraction and declining investment income. The dividend cut to $0.035 improves coverage, yet persistent NAV erosion and bearish analyst sentiment suggest limited near-term upside. Investors should weigh the attractive yield against fundamental deterioration and technical weakness.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
